Medtronic gets Medicare coverage for leadless pacemaker

Micra Transcatheter Pacing System (right) compared with a traditional pacemaker. (Medtronic)

Medtronic has secured Medicare coverage for its leadless pacemaker, Micra Transcatheter Pacing System (TPS). The Centers for Medicare & Medicaid Services (CMS) agreed to cover Micra TPS through its Coverage with Evidence Development, a policy that adds products to Medicare provided the manufacturer generates additional data.

The terms of the agreement mean Medicare, a U.S. federal health insurance program for people aged 65 or older, will only start covering Micra TPS once the CMS has approved two studies. Medtronic is seeking coverage of an existing postapproval trial and a planned study tracking longitudinal data on patients in the Medicare population. The postapproval trial is looking at the acute complication rate and long-term complication-free survival in patients who receive Micra TPS in the real world.

By adding a study focused on the Medicare population to its postapproval activities, Medtronic has secured Medicare coverage of patients in the trials nine months after FDA cleared the device for use in people who need a single-chamber pacemaker.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"Medtronic is pleased with the CMS decision to cover leadless pacemakers, which will allow broad patient access to this novel, minimally invasive pacemaker technology through an innovative approach to evidence and data collection to address research questions identified by CMS," Medtronic SVP John Liddicoat said in a statement.

Micra TPS stands apart from traditional pacemakers because of its size. At one inch long, the device is considerably smaller—Medtronic claims 93% smaller—than traditional pacemakers. And, unlike the competition, it is leadless. The device is hooked on to the heart using small prongs.

Medtronic thinks the design cuts the risk of complication. The complication rate in a 719-person trial came in below 7%. Subsequent long-term follow-up data linked Micra TPS to a 47% drop in risk of hospitalization and an 82% fall in the risk of the device needing removal, repositioning or replacement.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.